Identifying Changes in Blood (Potential Biomarkers) in Individuals With Drug-Induced Liver Injury

The purpose of this study is to try to develop new blood tests that may help doctors identify if a drug is hurting a person's liver.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Drug Induced Liver Injury Chemical and Drug Induced Liver Injury Chemically-Induced Disorders Digestive System Diseases Drug-Related Side Effects and Adverse Reactions Liver Diseases Poisoning

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of North Carolina

Chapel Hill, North Carolina, 27599, United States

About this study

Our hypothesis is that there are liver-specific particles, called mRNA, that are identifiable in a person's blood sample during liver injury caused by some drugs. The purpose of this study is to try to develop new blood tests that may help doctors identify if a drug is hurting a person's liver, perhaps early in the process before significant injury or illness have occurred.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

ALT > 200 IU/L at presentation to UNC Hospitals
Drug induced liver injury considered likely by admitting medical staff

Sponsors and collaborators

Lead sponsor

University of North Carolina, Chapel Hill

Other

Registry information

Official study title

Identification of New Biomarkers of Drug Induced Liver Injury

Important dates

Study start: 2009
Primary completion: 2013
Study completion: 2013
First posted: Oct 23, 2009
Registry last updated: Apr 18, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed